Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →
Cigna Group
CIHealthcareGenerated Jul 5, 2026, 08:08 PM UTC
CI (Cigna Group) analytical snapshot. Revenue grew +8.2% YoY to $195.26B. 5-year revenue CAGR +4.9%. Net margin at 2.64% (expanding ▲). Market cap $76.12B at $287.77 per share. Trailing P/E 16.55, P/S 0.39, P/B 1.80. EV/Operating income ≈ 12.72 (EV $108.61B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score 9 (data confidence 79%). Descriptive analytics from public filings — not investment advice.
Market cap
$76.12B
264.53M shares
Price
$287.77
NYQ
P/E (ttm)
16.55
Revenue (FY)
$195.26B
YoY +8.2%
Net margin
2.64%
▲ 2.64pp
Free cash flow
—
Risk level
Elevated
Free SEC analysis
— computed from SEC filings, free to readFree previewFundamentals Analyst
Fundamentals
Fundamentals Analyst
score 25Improving
80% conf
Revenue grew +8.2% YoY to $195.26B. 5-year revenue CAGR +4.9%. Net margin at 2.64% (expanding ▲).
- Revenue grew +8.2% YoY to $195.26B.
- 5-year revenue CAGR +4.9%.
- Net margin at 2.64% (expanding ▲).
- Return on equity 12.58%, ROA 3.31%, ROIC 20.80%.
- Gross margin 0.00%, operating margin 4.37%.
- Debt/equity 0.94, current ratio 0.82, net debt $32.48B.
- Asset turnover 1.27 — capital efficiency.
Revenue (FY)
$195.26B
YoY +8.2%
Net margin
2.64%
▲ 2.64pp
ROE
12.58%
ROA 3.31%
ROIC
20.80%
EPS (diluted)
$17.39
FY2025
Free cash flow
—
Debt / equity
0.94
Cash $7.04B
Current ratio
0.82
Equity $42.21B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2018 | $39.84B | — | 0.00 | 7.75 | 0.00 | $3.56B | 0.00 |
| 2019 | $41.81B | +4.9% | 0.00 | 9.43 | 0.00 | $3.62B | 0.00 |
| 2020 | $48.65B | +16.4% | 0.00 | 8.55 | 0.00 | — | 0.00 |
| 2021 | $153.57B | +215.7% | 0.00 | 5.26 | 0.00 | — | 0.00 |
| 2022 | $160.40B | +4.5% | 0.00 | 5.08 | 0.00 | — | 0.00 |
| 2023 | $174.07B | +8.5% | 0.00 | 4.56 | 0.00 | — | 0.00 |
| 2024 | $180.52B | +3.7% | 0.00 | 4.68 | 0.00 | — | 0.00 |
| 2025 | $195.26B | +8.2% | 0.00 | 4.37 | 2.64 | — | 12.58 |
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Mar 31, 2025 | $65.50B | +14.4% | — | 2.02% |
| Jun 30, 2025 | $132.68B | +12.7% | +102.6% | — |
| Jun 30, 2025 | $67.18B | -43.0% | -49.4% | — |
| Sep 30, 2025 | $202.43B | +11.5% | +201.3% | — |
| Sep 30, 2025 | $69.75B | -61.6% | -65.5% | — |
| Mar 31, 2026 | $68.49B | +4.6% | -1.8% | 2.41% |
Revenue (annual, SEC 10-K)
2018: 39,838
2019: 41,806
2020: 48,650
2021: 153,566
2022: 160,401
2023: 174,069
2024: 180,518
2025: 195,265
2018
2019
2020
2021
2022
2023
2024
2025
Profitability trends (%)
GrossOperatingNet
Free cash flow (annual)
2018: 3,565
2019: 3,615
2020: 0
2021: 0
2022: 0
2023: 0
2024: 0
2025: 0
2018
2019
2020
2021
2022
2023
2024
2025
Sources:SEC EDGAR — Company Facts (XBRL)
Free previewRegulatory Analyst
Filings & Ownership
Regulatory Analyst
score 30Improving
80% conf
Latest annual report (10-K) filed Feb 26, 2026. Latest quarterly report (10-Q) filed Apr 30, 2026. 20 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 26, 2026.
- Latest quarterly report (10-Q) filed Apr 30, 2026.
- 20 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Cigna Group; broad institutional reporting.
- Recent filers include XY Capital Ltd, TAM Capital Management Inc., TAM Capital Management Inc..
- 3 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 3 recent 13G passive institutional ownership notices.
Latest 10-K
Feb 26, 2026
Annual report
Latest 10-Q
Apr 30, 2026
8-K (recent)
20
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
3
Recent 13F institutional filers (SEC EDGAR full-text)
| Filer | Form | Filed |
|---|---|---|
| XY Capital Ltd | 13F-HR | Aug 5, 2024 |
| TAM Capital Management Inc. | 13F-HR | Aug 15, 2025 |
| TAM Capital Management Inc. | 13F-HR | Nov 14, 2025 |
| XY Capital Ltd | 13F-HR | May 12, 2026 |
| TAM Capital Management Inc. | 13F-HR | May 16, 2025 |
Recent 8-K material events
| Date | Form | Description |
|---|---|---|
| May 13, 2026 | 8-K | 8-K |
| Apr 30, 2026 | 8-K | 8-K |
| Apr 27, 2026 | 8-K | 8-K |
| Mar 3, 2026 | 8-K | 8-K |
| Feb 27, 2026 | 8-K | 8-K |
| Feb 5, 2026 | 8-K | 8-K |
| Nov 18, 2025 | 8-K | 8-K |
| Oct 30, 2025 | 8-K | 8-K |
Free previewSEC Filing Analyst
SEC Filing Deep-Analysis
SEC Filing Analyst
score -34Deteriorating
64% conf
2 risk signal(s), 1 watch item(s) detected from XBRL filing diff analysis. 2 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- Material weakness in internal controls: The term "material weakness" appears in 8 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- NEW: Restatement of financial statements in latest filing: The term "restate" "financial statements" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 6 filing(s).
- NEW: Impairment charge: Impairment charge appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- Endogenous analysis: 2 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 4 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 2 new risk-language term(s) detected in filing text: Restatement of financial statements, Impairment charge.
- Ongoing high-severity risk language: Material weakness in internal controls.
Revenue
$195.26B
+8.2% YoY
Operating income
$8.54B
+1.0% YoY
Net income
$5.16B
— YoY
Operating cash flow
$11.81B
+36.5% YoY
Capex
$471.0M
+2.2% YoY
Total assets
$155.88B
+2.0% YoY
Total liabilities
$114.64B
+7.7% YoY
Cash & equivalents
$7.55B
-3.5% YoY
Filing quality score
73/100
4 new disclosures
SEC XBRL metric changes (latest annual vs prior)
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $180.52B | $195.26B | $14.75B | +8.2% |
| Operating income | $8.45B | $8.54B | $86.0M | +1.0% |
| Net income | — | $5.16B | — | — |
| Operating cash flow | $8.66B | $11.81B | $3.16B | +36.5% |
| Capex | $461.0M | $471.0M | $10.0M | +2.2% |
| Total assets | $152.76B | $155.88B | $3.12B | +2.0% |
| Total liabilities | $106.41B | $114.64B | $8.23B | +7.7% |
| Cash & equivalents | $7.82B | $7.55B | $-272.0M | -3.5% |
| Stockholders equity | $46.22B | $41.03B | $-5.19B | -11.2% |
| Inventory | $5.64B | $6.69B | $1.05B | +18.5% |
| SG&A expense | $13.17B | $14.82B | $1.65B | +12.5% |
| Interest expense | $1.30B | $1.40B | $100.0M | +7.7% |
XBRL disclosure changes (new vs dropped concepts)
| Type | Concepts |
|---|---|
| Added | CashSurrenderValueDuePolicyholdersAmount, PolicyholderAccountBalanceNetAmountAtRisk, PolicyholderAccountBalanceWeightedAverageCreditingRate, PolicyholderContractDeposits |
| Removed | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment, AllocatedShareBasedCompensationExpense, AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries, AssetsHeldByInsuranceRegulators, AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent, CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations, CommercialPaper, CommonStockDividendsPerShareCashPaid, CommonStockSharesOutstanding, ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest |
Risk language in filing text (EDGAR full-text search)
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Material weakness in internal controls | high | 8 | 2 | Ongoing |
| Restatement of financial statements | high | 6 | 0 | NEW |
| Impairment charge | medium | 12 | 0 | NEW |
| Restructuring | medium | 11 | 2 | Ongoing |
| Off-balance sheet arrangements | medium | 17 | 2 | Ongoing |
| Related party transactions | low | 1 | 0 | NEW |
Filing signal breakdown
Red flags: 2
Positive: 0
Watch: 1
Red flags
Positive
Watch
Unlock the rest
- ProValuationMarket cap $76.12B at $287.77 per share.
- ProPrice & TechnicalsPrice $287.77 — uptrend (above 200-DMA); 1-month momentum positive.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Elevated.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite 9
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Cigna Group is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
16.59
Fed funds
3.63%
CPI YoY
+4.2%
Analytical read
deterministic previewRevenue grew **+8.2%** YoY to $195.26B..
Risk
Elevated
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Peer comparison
Defensive groupHow CI stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI● you | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Zoetis Inc. ZTS | 3 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Gilead Sciences GILD | 1 | Neutral |
| Intuitive Surgical Inc. ISRG | -1 | Neutral |
| Moderna Inc. MRNA | -4 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| DexCom Inc. DXCM | -7 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Kimberly-Clark Corp. KMB | -10 | Neutral |
| Sysco Corp. SYY | -10 | Neutral |
| Danaher Corp. DHR | -11 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Biogen Inc. BIIB | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| HCA Healthcare HCA | -14 | Neutral |
| Illumina Inc. ILMN | -16 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Hershey Co. HSY | -26 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |
| Thermo Fisher Scientific TMO | — | Neutral |
| Vertex Pharmaceuticals VRTX | — | Neutral |